The Impact of Open-Source AI Innovation on High-Tech Industrial Innovation Performance:Evidence from Cross-Country Panel Data of the Pharmaceutical Sector
Fan Saier1, Qi Yong1,2, Guo Qing3
1. School of Intellectual Property,Nanjing University of Science & Technology,Nanjing 210094,China; 2. School of Economics and Management,Nanjing University of Science & Technology,Nanjing 210094,China; 3. School of Public Management,Jiangsu Open University,Nanjing 210036,China
Abstract：The fusion of AI technologies and open-source innovation models is reshaping high-tech innovation paradigms,yet empirical evidence of its economic impact remains scarce.Taking the technology-and-capital-intensive pharmaceutical industry as the research context,this study integrates data from the GitHub open-source community and industrial economic statistics to construct a cross-country panel dataset(2008-2023).Adopting a multi-period lagged two-way fixed effects model combined with the instrumental variable method,this paper empirically examines the impacts and mechanisms of open-source AI innovation on the innovation performance of the pharmaceutical industry.Results show that such innovation significantly boosts performance,with financing performance acting as a mediator.Furthermore,open-source licensing positively moderates the relationship between open-source AI innovation and financing performance.Heterogeneity analysis reveals stronger effects in countries with upper-middle incomes,advanced financial systems,and moderate intellectual property protection.This study provides new empirical evidence for understanding the economic implications of open-source AI innovation,enriches research on the driving factors behind innovation performance of the pharmaceutical industry,and offers policy and managerial implications for boosting the innovation capacity of the pharmaceutical sector.
樊赛尔, 戚湧, 郭青. 人工智能开源创新对高技术产业创新绩效的影响研究——基于制药产业的跨国面板数据[J]. 中国科技论坛, 2026(7): 60-69.
Fan Saier, Qi Yong, Guo Qing. The Impact of Open-Source AI Innovation on High-Tech Industrial Innovation Performance:Evidence from Cross-Country Panel Data of the Pharmaceutical Sector. , 2026(7): 60-69.
[1] 刘仲仪.创新药产业发展:经济属性、关键挑战与推进路径[J].福建师范大学学报(哲学社会科学版),2025(3):60-68,169. [2] Wu Yifan,Yuan Yiming,Song Xueyin.The impact of AI adoption on R&D productivity:evidence from Chinese pharmaceutical manufacturing industry[J].Journal of Asian Economics,2025,97:101890. [3] Fuhen C,Chen Qiuchen.The future of pharmaceuticals:artificial intelligence in drug discovery and development[J].Journal of Pharmaceutical Analysis,2025,15(8):101248. [4] Bonaccorsi A,Rossi C.Why open source software can succeed[J].Research Policy,2003,32(7):1243-1258. [5] Balasegaram M,Kolb P,Mckew J,et al.An open source pharma roadmap[J].PLoS Medicine,2017,14(4):e1002276. [6] Schuhmacher A.Exploring open source as a strategy to enhance R&D productivity[J].Expert opinion on drug discovery,2024,19(12):1399-1402. [7] Lerner J,Schankerman M.The comingled code:Open source and economic development[M].Cambridge:MIT Press Books,2010. [8] Wright N,Nagle F,Greenstein S.Open source software and global entrepreneurship[J].Research Policy,2023,52(9):104846. [9] Blind K,Schubert T.Estimating the GDP effect of open source software and its complementarities with R&D and patents:evidence and policy implications[J].The Journal of Technology Transfer,2024,49(2):466-491. [10] 李亚玲,包芊颖,黄成凤.人工智能驱动科研范式变革的机制与路径研究:以生物学为例[J].中国科技论坛,2024(4):12-21. [11] Pun Frank,Ozerov I,Zhavoronkov A.AI-powered therapeutic target discovery[J].Trends in Pharmacological Sciences,2023,44(9):561-572. [12] 王楠,王国强.新竞争格局下中美生物医药创新对比研究[J].中国软科学,2023(1):22-31. [13] 陈文俊,彭有为,胡心怡.战略性新兴产业政策是否提升了创新绩效[J].科研管理,2020,41(1):22-34. [14] 丁佐奇,徐韩涵.数智化转型、知识管理能力与企业创新绩效:以医药制造业为例[J].现代经济探讨,2025(7):81-90. [15] 袁红梅,田会静,刘心蕊,等.动态网络能力、技术融合能力对生物医药新产品开发绩效的影响:企业创新绩效的中介效应[J].科技进步与对策,2024,41(18):108-118. [16] Banerjee T,Siebert R.Dynamic impact of uncertainty on R&D cooperation formation and research performance:evidence from the bio-pharmaceutical industry[J].Research Policy,2017,46(7):1255-1271. [17] 郭海,李晓宇,黄冉.开放参与对开源软件项目绩效的影响研究:基于开放悖论视角[J].科学学与科学技术管理,2024,45(3):90-111. [18] Romer P.Endogenous technological change[J].Journal of Political Economy,1990,98(5):S71-S102. [19] Kang H.Pharmaceutical start-ups' technology and financing strategy[J].Journal of Pharmaceutical Innovation,2018,13(4):301-312. [20] Akerlof G.The market for“lemons”:quality uncertainty and the market mechanism[J].The Quarterly Journal of Economics,1970,84(3):488-500. [21] 刘云,房浩超.人工智能赋能产业创新生态系统动态演进:驱动因素与具体路径[J].科技进步与对策,2025,42(13):1-13. [22] 周泽将,马静,胡子木.私募股权投资主导IPO:行为逻辑与策略选择:基于高特佳控股博雅生物的案例研究[J].审计与经济研究,2017,32(3):68-77. [23] Spence M.Job market signaling[J].The Quarterly Journal of Economics,1973,87(3):355. [24] 李兰花,陈真真,黄灿,等.开源许可规制、技术复杂度与开源项目可持续发展:基于GitHub大样本实证研究[J].科研管理,2026,47(3):189-198. [25] Leelananda S,Lindert S.Computational methods in drug discovery[J].Beilstein Journal of Organic Chemistry,2016,12(1):2694-2718. [26] Cohen W,Levinthal D.Absorptive capacity:a new perspective on learning and innovation[J].Administrative Science Quarterly,1990,35(1):128-152. [27] Teece D.Profiting from technological innovation:implications for integration,collaboration,licensing and public policy[J].Research policy,1986,15(6):285-305. [28] Sun Duxin,Gao Wei,Hu Hongxia,et al.Why 90% of clinical drug development fails and how to improve it[J].Acta Pharmaceutica Sinica B,2022,12(7):3049-3062. [29] 闫旭东,吴晓光,张宏飞,等.基于改进综合指标法的内蒙古自治区农村居民点整治潜力评估及分区[J].干旱区资源与环境,2017,31(9):163-169. [30] 陈林生,李止兮.中国区域增长差异变动的影响因素研究:基于2010—2020年数据[J].云南财经大学学报,2023,39(8):38-51. [31] 吴淑娥,仲伟周,卫剑波,等.融资来源、现金持有与研发平滑:来自我国生物医药制造业的经验证据[J].经济学(季刊),2016,15(2):745-766.
2026, 
